Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review.
disease-free survival
first relapse
hyperthermic intraperitoneal chemotherapy
ovarian cancer
progression-free survival
secondary surgery
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Dec 2021
30 Dec 2021
Historique:
received:
29
11
2021
revised:
20
12
2021
accepted:
24
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
Hyperthermic intraperitoneal chemotherapy (HIPEC) is routinely used in the treatment of a first ovarian cancer relapse. This systematic review, in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, aimed to assess the quality of scientific proof of the survival benefits of HIPEC, using Medline and Google Scholar. Qualitative analysis using the Oxford CEBM Levels of Evidence 2011 grading is reported. Of 469 articles identified, 23 were included; 15 based on series of patients treated with HIPEC without a control group, and 8 case control series of patients treated with or without HIPEC. The series without a control group showed median overall survival (OS) ranged from 23.5 to 63 months, highlighting a broad standard deviation. Considering the case control series, OS was significantly better in the HIPEC group in 5 studies, and similar in 1. The current review showed considerable heterogeneity and biases, with an Oxford Level of Evidence grading of 4 for 22 selected series and 2 for one. There is no strong evidence to suggest efficacy of HIPEC in improving survival of patients treated for a first relapse of ovarian cancer due to the low quality of the data.
Sections du résumé
BACKGROUND
BACKGROUND
Hyperthermic intraperitoneal chemotherapy (HIPEC) is routinely used in the treatment of a first ovarian cancer relapse.
METHODS
METHODS
This systematic review, in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, aimed to assess the quality of scientific proof of the survival benefits of HIPEC, using Medline and Google Scholar. Qualitative analysis using the Oxford CEBM Levels of Evidence 2011 grading is reported.
RESULTS
RESULTS
Of 469 articles identified, 23 were included; 15 based on series of patients treated with HIPEC without a control group, and 8 case control series of patients treated with or without HIPEC. The series without a control group showed median overall survival (OS) ranged from 23.5 to 63 months, highlighting a broad standard deviation. Considering the case control series, OS was significantly better in the HIPEC group in 5 studies, and similar in 1. The current review showed considerable heterogeneity and biases, with an Oxford Level of Evidence grading of 4 for 22 selected series and 2 for one.
CONCLUSIONS
CONCLUSIONS
There is no strong evidence to suggest efficacy of HIPEC in improving survival of patients treated for a first relapse of ovarian cancer due to the low quality of the data.
Identifiants
pubmed: 35008336
pii: cancers14010172
doi: 10.3390/cancers14010172
pmc: PMC8750536
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Eur J Surg Oncol. 2009 Nov;35(11):1186-91
pubmed: 19356887
Oncologist. 2009 Jul;14(7):683-94
pubmed: 19608639
Clin Transl Oncol. 2009 Nov;11(11):753-9
pubmed: 19917539
Rev Med Liege. 2013 Dec;68(12):644-9
pubmed: 24564030
Ann Surg Oncol. 2017 Apr;24(4):914-922
pubmed: 27896512
J Cancer. 2018 Feb 16;9(5):872-879
pubmed: 29581765
Ann Surg Oncol. 2015 Mar;22(3):987-93
pubmed: 25212832
Int J Cancer. 2015 Feb 1;136(3):699-708
pubmed: 24895230
Evid Based Ment Health. 2020 May;23(2):83-87
pubmed: 32139442
Ann Surg Oncol. 2012 Jul;19(7):2352-9
pubmed: 20039210
Ann Surg Oncol. 2014 Oct;21(11):3621-7
pubmed: 24819120
J Surg Oncol. 2011 Jan 1;103(1):10-6
pubmed: 21031424
J Surg Oncol. 2010 Nov 1;102(6):663-70
pubmed: 20721959
Expert Rev Anticancer Ther. 2012 Jul;12(7):895-911
pubmed: 22845405
Ann Surg Oncol. 2015 May;22(5):1570-5
pubmed: 25391263
Gynecol Oncol. 2016 Aug;142(2):237-42
pubmed: 27246305
Gynecol Oncol. 2011 Aug;122(2):221-5
pubmed: 21543112
Int J Gynecol Cancer. 2012 Jun;22(5):778-85
pubmed: 22572845
Ann Surg Oncol. 2016 May;23(5):1660-5
pubmed: 26714958
Gland Surg. 2020 Aug;9(4):1140-1148
pubmed: 32953629
Rev Lat Am Enfermagem. 2007 May-Jun;15(3):508-11
pubmed: 17653438
Acta Obstet Gynecol Scand. 2015 Apr;94(4):435-9
pubmed: 25675854
Eur J Obstet Gynecol Reprod Biol. 2014 Aug;179:88-93
pubmed: 24965986
Int J Gynecol Cancer. 2016 May;26(4):661-70
pubmed: 26844612
Lancet. 2019 Mar 23;393(10177):1240-1253
pubmed: 30910306
Int J Gynecol Cancer. 2010 Jan;20(1):61-9
pubmed: 20130504
Eur J Gynaecol Oncol. 2016;37(5):638-643
pubmed: 29787001
World J Surg. 2004 Oct;28(10):1040-5
pubmed: 15573262
Anticancer Res. 2015 Sep;35(9):4997-5005
pubmed: 26254399
Patient Saf Surg. 2012 Jun 15;6(1):12
pubmed: 22709648
J Surg Oncol. 2006 Sep 15;94(4):316-24
pubmed: 16917864
J Surg Oncol. 2014 Nov;110(6):661-5
pubmed: 24962381
World J Surg Oncol. 2004 Jun 28;2:21
pubmed: 15222884
World J Surg. 2007 Sep;31(9):1813-1820
pubmed: 17629740
JAMA Netw Open. 2020 Jan 3;3(1):e1918939
pubmed: 31922558
Langenbecks Arch Surg. 2011 Oct;396(7):1077-81
pubmed: 21842290
Ann Surg Oncol. 2016 Apr;23(4):1294-301
pubmed: 26628430
Eur J Surg Oncol. 2006 Aug;32(6):671-5
pubmed: 16621425
Bull Cancer. 2010 Apr;97(4):E23-32
pubmed: 20202920
Minerva Chir. 2014 Feb;69(1):27-35
pubmed: 24675244
Eur J Surg Oncol. 2013 Oct;39(10):1109-15
pubmed: 23870278
Gynecol Oncol. 2012 Dec;127(3):502-5
pubmed: 23022234
BJOG. 2012 Jun;119(7):800-9
pubmed: 22571746
Cancer. 2008 Jul 15;113(2):315-25
pubmed: 18473354
Minerva Chir. 2014 Feb;69(1):17-26
pubmed: 24675243